VolitionRx Ltd


Cancer Diagnosis

Volition's goal is to make its non-invasive cancer blood tests as common and simple to use as existing diabetic and cholesterol tests on similar formats.

About Volition Watch Video


VolitionRx is developing a range of diagnostic tests for cancer and other conditions. Each test is based on the Nucleosomics® technology: measurement and identification of nucleosomes in the blood. Learn More About Our Technology ›

Colorectal Cancer

VolitionRx is currently assessing the efficacy of NuQ® for the diagnosis of colorectal cancers, in a number of clinical trials in Europe. Learn More About Colorectal Cancers ›

Upcoming Events

10th Annual Wells Fargo Healthcare Conference

Our Chief Executive Officer, Cameron Reynolds, will host 1-on-1 meetings all day on September 10.  If you would like to schedule a 1-on-1 meeting with VolitionRx management during the conference, please contact your Wells Fargo representative, or Lee Roth or Joseph Green of The Ruth Group at lroth@theruthgroup.com or jgreen@theruthgroup.com.  

Boston, MA

View Events Calendar ›

Stock Data View Investor Relations ›

Market Cap
Sign Up Today

We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. If you continue to browse the site, you will accept our use of cookies.